Table 1.
Most significant proteins differentially expressed in plasma of ApoE−/−/LDLR−/− vs. wild-type mice as revealed by proteomic analysis (the ratio is given as ApoE−/−/LDLR−/−/control)
| No | UniProtKB ID/Accession number | Q value | Ratio | Peptide count | Protein annotation (Short name) |
Involvement in the biological process |
|---|---|---|---|---|---|---|
| 1 | P15535 | N/A* | Only in 2# | 2 |
Beta-1,4-galactosyltransferase 1 (Beta-1,4-GalTase 1) |
Protein glycosylation |
| 2 | P07310 | N/A | Only in 1# | 2 | Creatine kinase M-type (M-CK) | Energy transduction/Creatine metabolism |
| 3 | P29533 | N/A | Only in 1 | 2 | Vascular cell adhesion protein 1 (VCAM-1) | Leukocyte-endothelial cell adhesion |
| 4 | P02468 | N/A | Only in 1 | 2 | Laminin subunit gamma-1 (S-LAM gamma) | Cell adhesion |
| 5 | P24270 | N/A | Only in 2 | 2 | Catalase (Cat) | Detoxification of Reactive Oxygen Species |
| 6 | O89023 | N/A | Only in 1 | 2 | Tripeptidyl-peptidase 1 (TPP-1) | Peptide catabolic process/Vessels wall injury |
| 7 | P63017 | N/A | Only in 1 | 2 | Heat shock cognate 71 kDa protein (Hspa8) | Molecular chaperone implicated in a wide variety of cellular processes associated with proteome organization |
| 8 | P04918 | N/A | Only in 1 | 5 | Serum amyloid A-3 protein (SAA3) | Acute-phase response |
| 9 | P06728 | 0.00003 | 0.57 | 64 | Apolipoprotein A-IV (ApoA-IV) | Lipid transport/metabolism |
| 10 | P13020 | 0.00003 | 0.00003 | 31 | Gelsolin (GSN) | A key component of the innate immune system |
| 11 | E9Q414 | 0.00003 | 1.44 | 339 | Apolipoprotein B-100 (ApoB-100) | Lipid transport/metabolism |
| 12 | P05366 | 0.00003 | 3.13 | 11 | Serum amyloid A-1 protein (SAA1) | Acute-phase response |
| 13 | P05367 | 0.00003 | 3.34 | 15 | Serum amyloid A-2 protein (SAA2) | Acute-phase response |
| 14 | A6X935 | 0.00003 | 1.38 | 72 | Inter alpha-trypsin inhibitor, heavy chain 4 (ITI-HC4) | Acute-phase response/Hyaluronan metabolic process |
| 15 | Q61838 | 0.00073 | 0.82 | 81 | Alpha-2-macroglobulin (Alpha-2-M) | Disruption of inflammatory cascade/Serine protease inhibition |
| 16 | Q921I1 | 0.00077 | 0.43 | 23 | Serotransferrin (Transferrin/STF) | Iron transport |
| 17 | P07309 | 0.00082 | 0.71 | 9 | Transthyretin (TTR) | Retinoid metabolism and transport |
| 18 | P12246 | 0.00367 | 2.55 | 10 | Serum amyloid P-component (SAP) | Acute-phase response |
| 19 | P06683 | 0.00377 | 1.44 | 17 | Complement component C9 (C9) | Complement alternate pathway |
| 20 | Q91X72 | 0.00489 | 0.58 | 22 | Hemopexin (HPX) | Scavenging of heme from plasma |
| 21 | P31532 | 0.01109 | 21.671 | 14 | Serum amyloid A-4 protein (SAA4) | Acute-phase response |
| 22 | P07758 | 0.01969 | 1.46 | 14 | Alpha-1-antitrypsin 1-1 (Serpina 1a) | Acute-phase response |
| 23 | Q00896 | 0.01969 | 1.39 | 14 | Alpha-1-antitrypsin 1-3 (Serpina 1c) | Acute-phase response |
| 24 | P04186 | 0.02333 | 1.35 | 17 | Complement factor B (CFB) | Complement alternate pathway |
| 25 | P22599 | 0.03604 | 1.44 | 6 | Alpha-1-antitrypsin 1-2 (Serpina 1b) | Acute-phase response |
| 26 | Q80W65 | 0.03649 | 1.83 | 11 | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | Cholesterol metabolism |
| 27 | Q8BPB5 | 0.03766 | 0.73 | 7 | EGF-containing fibulin-like extracellular matrix protein 1 (FIBL-3) | A growth factor in the arteries |
| 28 | P51885 | 0.03795 | 1.58 | 17 | Lumican (LUM) | Collagen fibril organization |
| 29 | P06909 | 0.03892 | 1.31 | 23 | Complement factor H (CFH) | Complement alternate pathway |
| 30 | P28653 | 0.03905 | 1.95 | 13 | Biglycan (BGN) | Blood vessel remodelling |
| 31 | Q60994Q60994 | 0.039430.03943 | 0.45 | 6 | Adiponectin (AdipoQ/APN) | Negative regulation of tumor necrosis factor-mediated signaling pathway |
| 32 | P70375 | 0.04003 | 1.55 | 9 | Coagulation factor VII (FVII) | Blood coagulation |
| 33 | Q08761 | 0.04005 | 0.79 | 12 | Vitamin K-dependent protein S (VKDP-S) | Prevention of coagulation/Fibrinolysis stimulation |
| 34 | Q9Z1T2 | 0.04106 | 1.47 | 2 | Thrombospondin-4 (TSP-4) | Endothelial cell–cell adhesion/Tissue remodelling |
| 35 | Q8K0E8 | 0.04213 | 1.62 | 10 | Fibrinogen beta chain (FGB) | Blood coagulation |
| 36 | Q9QXC1 | 0.04378 | 1.54 | 4 | Fetuin-B (FETUB) | Regulation of vascular plaque-stabilizing factors |
| 37 | O08677 | 0.04451 | 1.29 | 19 | Kininogen-1 (KNG1) | Blood coagulation |
| 38 | P09470 | 0.04568 | 1.66 | 28 | Angiotensin-converting enzyme (ACE) | Angiotensin II generation/Bradykinin inactivation |
| 39 | P26262 | 0.04571 | 1.48 | 11 | Plasma kallikrein (pKal) | Blood coagulation/Inflammatory response |
| 40 | O08538 | 0.04864 | 1.62 | 8 | Angiopoietin-1 (ANG-1) | Regulation of blood vessel endothelial cell migration/cell adhesion/monocyte recruitment and retention |
| 41 | Q8CIZ8 | 0.04903 | 1.83 | 19 | Von Willebrand factor (vWF) | Blood coagulation/Cell adhesion/Platelet activation |
| 42 | P34928 | 0.049540.04954 | 1.54 | 7 | Apolipoprotein C-I (ApoC-I) | Lipid transport/metabolism |
| 43 | P18242 | 0.04966 | 1.38 | 4 | Cathepsin D (Cath-D) | Cleavage of angiotensinogen to produce angiotensin I/Renin-like activity |
| 44 | P33622 | 0.04986 | 1.47 | 8 | Apolipoprotein C-III (ApoC-III) | Lipid transport/metabolism |
| 45 | P04202 | 0.04997 | 1.44 | 8 | Transforming growth factor beta-1 (TGF-beta-1) | Controlling of proliferation, differentiation and cell migration/Induction of epithelial-to-mesenchymal transition |
| &46 | P52430 | 0.05003 | 0.58 | 25 | Serum paraoxonase/arylesterase 1 (PON-1) | Enzymatic protection of low-density lipoproteins against oxidative modification |
| &47 | P46412 | 0.05015 | 0.72 | 10 | Glutathione peroxidase 3 (GPx-3) | Detoxification of Reactive Oxygen Species |
* N/A – not applicable; # only in 1 refers to ApoE/LDLR−/−, whereas in 2 refers to controls
& These proteins were involved in the table (despite q-value slightly higher than 0.05) as they support biological conclusion about profoundly affected anti-oxidative defense mechanisms in response to dyslipidaemia